# Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma

> **NCT06508827** · PHASE2 · WITHDRAWN · sponsor: **Indiana University**

## Conditions studied

- Anemia, Iron Deficiency
- Melanoma

## Interventions

- **DRUG:** Iron dextran 1000 mg IV

## Key facts

- **NCT ID:** NCT06508827
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-05
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Difficulty recruiting participants
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06508827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06508827, "Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06508827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*